Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Rezolute, Inc. (RZLT)

1.92   0.02 (1.03%) 03-31 16:00
Open: 1.86 Pre. Close: 1.9005
High: 1.97 Low: 1.55
Volume: 22,406 Market Cap: 78(M)

Technical analysis

as of: 2023-03-31 4:21:52 PM
Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 2.63     One year: 3.13
Support: Support1: 1.55    Support2: 1.29
Resistance: Resistance1: 2.25    Resistance2: 2.68
Pivot: 2.03
Moving Average: MA(5): 1.95     MA(20): 2.13
MA(100): 2.03     MA(250): 2.57
MACD: MACD(12,26): -0.2     Signal(9): -0.2
Stochastic oscillator: %K(14,3): 28.7     %D(3): 21.6
RSI: RSI(14): 42.1
52-week: High: 4  Low: 1.34
Average Vol(K): 3-Month: 28 (K)  10-Days: 38 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ RZLT ] has closed above bottom band by 28.0%. Bollinger Bands are 12.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 1.97 - 1.98 1.98 - 1.99
Low: 1.54 - 1.55 1.55 - 1.56
Close: 1.9 - 1.92 1.92 - 1.94

Company Description

Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, a selective and potent plasma kallikrein inhibitor, which is in Phase 1 clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.

Headline News

Wed, 29 Mar 2023
Insiders who bought stock earlier this year lose -US$195k as Rezolute, Inc. (NASDAQ:RZLT) drops to US$68m - Simply Wall St

Thu, 23 Mar 2023
Rezolute KOL Event Highlights Significant Unmet Medical Need in ... - GlobeNewswire

Wed, 08 Mar 2023
Rezolute to Highlight RZ402 Phase 2 Clinical Program with Leading Clinical Expert -

Wed, 15 Feb 2023
GlycoMimetics stock falls after 11.8M stock offering (NASDAQ:GLYC) - Seeking Alpha

Fri, 10 Feb 2023
Rezolute Reports Second Quarter Fiscal 2023 Results and ... - GlobeNewswire

Thu, 02 Feb 2023
After losing 37% in the past year, Rezolute, Inc. (NASDAQ:RZLT) institutional owners must be relieved by the recent gain - Yahoo Eurosport UK

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 37 (M)
Shares Float 26 (M)
% Held by Insiders 21.6 (%)
% Held by Institutions 70.2 (%)
Shares Short 190 (K)
Shares Short P.Month 218 (K)

Stock Financials

EPS -3.02
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 4.3
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -28.6
Return on Equity (ttm) -49.4
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -1.21
Qtrly Earnings Growth 0
Operating Cash Flow -41 (M)
Levered Free Cash Flow -24 (M)

Stock Valuations

PE Ratio -0.64
PEG Ratio 0
Price to Book value 0.44
Price to Sales 0
Price to Cash Flow -1.74

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date 2020-10-12
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.